



Press Release

TSXV: ADK

For immediate distribution
Source: DIAGNOS inc.

2011.02.08

DIAGNOS - New partner in Vietnam for the commercialization of CARA

Brossard, Quebec, Canada – February 8, 2011 - DIAGNOS inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK), a leader in the use of artificial intelligence and advanced knowledge-extraction techniques, announces that Alphi Investment (“ALPHI”) is the representative of DIAGNOS for the commercialization of CARA in Vietnam.

The CARA suite of applications allows the different players in the diabetic retinopathy screening process to make better informed decisions and extend cost-effective care to a larger patient population. “Our global market penetration strategy is to address countries with a high diabetes rate, Vietnam being one of those markets. The Business Manager of ALPHI, Mr. Nguyen Quang Quy, has both Canadian and Vietnamese citizenship and has helped many Canadian companies develop new business opportunities in Vietnam”, said Yvan Michon, Manager – Business Development of DIAGNOS.

According to a 2010 study conducted in Vietnam by Mr. Ta Van Binh, PhD. MD, Director of the Vietnam Ministry of Health, National Institute of Diabetes and Metabolic Disorders, diabetes increased by 500% over the last decade and people affected by this disease is estimated at 3.5 to 4.0 million.

The Corporation’s management is confident that CARA will generate new streams of revenues in Vietnam based on these factors:

- All diabetics need to be screened annually for diabetic retinopathy to reduce the risk of visual impairment and ultimately blindness and other co-morbidities as well as to monitor for progression of disease;
- Screening of diabetic patients for the presence of retinopathy is currently done, for the most part, manually by ophthalmologists and therefore is not optimized to efficiently and cost-effectively handle the burgeoning diabetic population – the number of ophthalmologists with a retina sub-specialty and available to perform screening is inadequate to handle the volume of diabetic patients requiring screening;
- Automating the screening process with CARA creates several efficiencies, including (1) reduction of congestion at tertiary health centres (2) optimization of specialist time (3) better health outcomes for diabetics and (4) cost savings to the health care system.

About CARA

CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care (POC) and comprises: image upload, image enhancement automated pre-screening, grading by a specialist, and referral to a specialist. CARA’s image enhancement algorithms make standard retinal images sharper, clearer, and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras. CARA is a cost-effective tool for processing large numbers of images, in real-time and has been issued a licence by Health Canada for commercialization in Canada.

About ALPHI

Alphi Investment is a Vietnamese based company with operations in Canada. ALPHI’s mission is to help Canadian and Vietnamese organizations put in place bilateral cooperation agreements in the medical field and other technologies.



DIAGNOS

Your Knowledge Partner

TSXV: ADK

For immediate distribution
Source: DIAGNOS inc.

About DIAGNOS

Founded in 1998, DIAGNOS is a publicly traded Canadian corporation with a mission to commercialize technologies combining contextual imaging and traditional data mining thereby improving decision making processes. DIAGNOS offers products, services, and solutions to clients in a variety of fields including natural resources, healthcare, and entertainment.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this press release.

For further information, please visit our website at www.diagnos.com or the SEDAR website at www.sedar.com. You may also contact our investor relations representative:

André Larente, President and CEO

Telephone: 1-877-678-8882 or (450) 678-8882, ext.: 224

alarente@diagnos.com